About eflornithine
Ornithine decarboxylase inhibitor
Used for
- Reduces the risk of relapse in high-risk neuroblastoma after response to initial treatment.
Usual adult dose
Adults: 768 mg/m² by mouth twice daily, based on body surface area.
Usual dose in children
Children: 768 mg/m² by mouth twice daily, based on body surface area.
Common side effects
- Hearing loss
- Infections
- Reduced appetite
- Vomiting or diarrhea
Important warnings
- Hearing can worsen; hearing tests are needed before and during treatment.
- Blood tests monitor liver function and blood counts.
- Treatment is supervised by specialists experienced in neuroblastoma.
- The dose may need adjustment for kidney problems.
Pregnancy
May harm an unborn baby; pregnancy testing and effective contraception are recommended during treatment and for one week afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the final dose.
Interactions
- No major drug interactions are established; provide the treatment team with a complete medication list.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.